Lytix Biopharma AS

DB:6BG Stock Report

Market Cap: €32.0m

Lytix Biopharma Future Growth

Future criteria checks 2/6

Lytix Biopharma is forecast to grow revenue at 137.9% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth42.5%
Revenue growth rate137.9%
Future return on equityn/a
Analyst coverage

Low

Last updated29 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:6BG - Analysts future estimates and past financials data (NOK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026232N/AN/A2131
12/31/202523N/AN/A-331
12/31/20246N/AN/A-751
9/30/202411-81-82-82N/A
6/30/202414-76-87-87N/A
3/31/202415-86-101-101N/A
12/31/20234-88-96-96N/A
9/30/202314-99-95-95N/A
6/30/202311-91-78-78N/A
3/31/202311-61-55-55N/A
12/31/202211-56-53-53N/A
9/30/20228-43-38-38N/A
6/30/20223-51106106N/A
3/31/20224-63-56-56N/A
12/31/202119-48-45-45N/A
9/30/20214-44-39-39N/A
6/30/20217-40-185-185N/A
3/31/20216-35-25-25N/A
12/31/20204-42-24-24N/A
12/31/20196-33-37-37N/A
12/31/201812-62-73-73N/A
12/31/201714-69N/A-70N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6BG's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 6BG's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if 6BG's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 6BG's revenue (137.9% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: 6BG's revenue (137.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 6BG's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y